RAPT Therapeutics (NASDAQ:RAPT) Announces Earnings Results, Misses Estimates By $0.69 EPS

RAPT Therapeutics (NASDAQ:RAPT) announced its earnings results on Thursday. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.69), Zacks reports.

RAPT Therapeutics Stock Up 2.2 %

Shares of RAPT stock traded up $0.03 during trading hours on Thursday, hitting $1.16. 130,800 shares of the company’s stock were exchanged, compared to its average volume of 827,314. The firm has a 50 day moving average of $1.27 and a two-hundred day moving average of $1.57. RAPT Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $10.05. The firm has a market cap of $40.38 million, a P/E ratio of -0.42 and a beta of -0.31.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on RAPT. Stifel Nicolaus reaffirmed a “hold” rating and set a $2.00 price objective (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $8.00 to $2.00 in a research report on Monday, November 11th. HC Wainwright upgraded shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Thursday, December 26th. Finally, Wells Fargo & Company lowered their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $5.29.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.